



Aurobindo Pharma Gets USFDA Approval For Duloxetine Hydrochloride CapsulesPosted Atstockmarketsreview.com(RTTNews) - The Hyderabad-based Aurobindo Pharma Ltd. announced that the company had received tentative approval from the US FDA to manufacture and market Duloxetine Hydrochloride Delayed-Release capsules 20mg (base), 30mg (base) and 60mg (base). Duloxetine Hydrochloride Delay-Release capsules are the generic equivalent of Eli Lilly and Company's Cymbalta Delayed-Release capsules 20mg (base), 30mg (base) and 60mg (base). Duloxetine Hydrochloride Delayed-Release capsules are indicated for the treatment of major depressive disorder and fall under the Neurological therapeutic category. As per IMS data, the product has a market size of around $2.9 billion for the twelve months ended June 2010. At the BSE, Aurobindo Pharma shares are being traded at Rs.1,301, up by 0.143% from the previous close. December 08, 2010
|